CD1a-CAR T Cell Therapy(Onechain)

N/A

Report date: 2023/12/08 16:47:33

Base Information

Drug NameCD1a-CAR T Cell Therapy(Onechain)
Drug Alias NamehCD1a-CAR T (OC-1) Therapy(Onechain)SNUH-CD19-CAR-T
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-T-cell surface glycoprotein CD1a
TargetsT-cell surface glycoprotein CD1a
Therapy Area/IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOnechain Immunotherapeutics SL
China Registration ClassN/A

Develop Information

Active CompaniesOnechain Immunotherapeutics SL
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A